GLP-1 Receptor Agonist Exposure Linked to Neovascular AMD in Patients With Diabetes
By Elana Gotkine HealthDay Reporter
FRIDAY, June 6, 2025 -- For patients with diabetes, exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased risk for incident neovascular age-related macular degeneration (nAMD) development, according to a study published online June 5 in JAMA Ophthalmology.
Reut Shor, M.D., from the University of Toronto in Canada, and colleagues examined the risk for developing nAMD associated with GLP-1 RA use in patients with diabetes in a population-based, retrospective cohort study. Patients aged 66 years or older with a diagnosis of diabetes and a minimum follow-up period of 12 months following initial diabetes diagnosis were included in the study. A matched cohort of 139,002 patients was created, with 46,334 patients exposed to GLP-1 RAs and 92,668 unexposed patients.
The researchers found that the exposed cohort had a higher incidence of nAMD than the unexposed cohort. Both unadjusted (crude) and adjusted models estimated hazard ratios for nAMD development of greater than 2.0 among patients exposed to GLP-1 RAs (crude hazard ratio, 2.11; adjusted hazard ratio, 2.21).
"While these findings align with the existing literature favoring a hypoxic-dependent mechanism of nAMD, diabetic retinopathy, and nonarteritic anterior ischemic optic neuropathy exacerbation, further research is needed to determine if there is a true cause-and-effect relationship in the association identified in this investigation and to understand the tradeoffs between the benefits and risks of GLP-1 RAs," the authors write.
"We want to know what the effects of these drugs are because we know that there are receptors for GLP-1 in the retina, and so it's reasonable to try to figure out what that might mean," said Talia Kaden, M.D., from Northwell Health in New York City, who was not involved in the study. "When you take into account all of the benefits that we know people have when they're on these medications, I don't think that this slight increase that we may be seeing in this particular cohort ... should be a reason for people to not be on these drugs."
One author disclosed ties to Alcon, Apellis, AbbVie, Bayer, Bausch Health, and Roche.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2025
Read this next
Rebound Weight Gain Common After Discontinuing Antiobesity Medications
FRIDAY, July 25, 2025 -- Antiobesity medications (AOMs) yield weight loss during use, followed by weight regain after discontinuation of treatment, according to a review published...
Prevalence of Extremely Severe Obesity Increasing in Children
TUESDAY, July 22, 2025 -- From 2008 to 2023, there was an increase in the prevalence of extremely severe obesity in children, especially among older adolescents and non-Hispanic...
Long-Term Obesity Linked to Expression of Aging Biomarkers
THURSDAY, July 17, 2025 -- Long-term obesity is associated with the expression of biomarkers denoting antagonistic and integrative aging hallmarks in adults aged 28 to 31 years...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.